Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;7(3):216-20.
doi: 10.1007/s11899-012-0127-0.

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways

Vaishalee P Kenkre  1 , Brad S Kahl
Affiliations
Review

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways

Vaishalee P Kenkre et al. Curr Hematol Malig Rep. 2012 Sep.

Abstract

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

PubMed Disclaimer

References

    1. J Immunol. 2006 May 15;176(10):5715-9 - PubMed
    1. N Engl J Med. 2010 Apr 15;362(15):1417-29 - PubMed
    1. Blood. 2011 Jan 13;117(2):591-4 - PubMed
    1. Nature. 2010 Jan 7;463(7277):88-92 - PubMed
    1. Blood. 2011 Jun 9;117(23):6287-96 - PubMed

MeSH terms

Substances

LinkOut - more resources